Washington HB 1689: Exempting biomarker testing from prior authorization for patients with late stage cancer.

Status: Prefiled for introduction. (as of 2022-12-22)

State: Washington · Session: 2021-2022 · Bill: HB 1689

Subjects: HEALTH AND SAFETY, PUBLIC, HEALTH CARE, INSURANCE

Sponsors: Walen, Davis, Duerr, Graham, Harris, Leavitt, Slatter, Tharinger

View Washington HB 1689 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.